<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Fosaprepitant: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Fosaprepitant: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Fosaprepitant: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9032" href="/d/html/9032.html" rel="external">see "Fosaprepitant: Drug information"</a> and <a class="drug drug_patient" data-topicid="12023" href="/d/html/12023.html" rel="external">see "Fosaprepitant: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F5634805"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Emend</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868941"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Emend</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F13313140"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antiemetic</span>;</li>
<li>
<span class="list-set-name">Substance P/Neurokinin 1 Receptor Antagonist</span></li></ul></div>
<div class="block dop drugH1Div" id="F51359177"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2791f691-127b-40fb-90cf-ead84edbdbb6">Chemotherapy-induced nausea and vomiting, prevention; highly and moderately emetogenic chemotherapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chemotherapy-induced nausea and vomiting, prevention;</b>
<b>highly and moderately emetogenic chemotherapy</b>
<b>:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months weighing ≥6 kg and Children &lt;2 years:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Single-dose <i>NK<sub>1</sub> receptor antagonist </i> regimen: </i>
<b>Note: </b>Use only with single-day chemotherapy regimens. IV: 5 mg/kg once; maximum dose: 150 mg/dose; administer ~90 minutes prior to chemotherapy on day 1 only; use in combination with a 5-HT<sub>3</sub> antagonist with or without corticosteroid.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Three-day NK<sub>1</sub> receptor antagonist regimen:</i>
<b>Note: </b>May be used with single-day or multiday chemotherapy regimens<i>. </i>Use in combination with a 5-HT<sub>3</sub> antagonist with or without corticosteroid.</p>
<p style="text-indent:-2em;margin-left:8em;">Day 1: Administer ~90 minutes prior to chemotherapy: IV: 3 mg/kg once; maximum dose: 115 mg/dose.</p>
<p style="text-indent:-2em;margin-left:8em;">Day 2 and 3: Administer ~90 minutes prior to chemotherapy: IV: 2 mg/kg once daily for 2 doses; maximum dose: 80 mg/dose; alternatively, may follow with oral aprepitant on days 2 and 3.</p>
<p style="text-indent:-2em;margin-left:4em;">Children 2 to &lt;12 years:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Single-dose <i>NK<sub>1</sub> receptor antagonist </i> regimen: </i>
<b>Note: </b>Use only with single-day chemotherapy regimens. IV: 4 mg/kg once; maximum dose: 150 mg/dose; administer ~90 minutes prior to chemotherapy on day 1 only; use in combination with a 5-HT<sub>3</sub> antagonist with or without corticosteroid.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Three-day <i>NK<sub>1</sub> receptor antagonist </i> regimen:</i>
<b>Note: </b>May be used with single-day or multiday chemotherapy regimens<i>. </i>Use in combination with a 5-HT<sub>3</sub> antagonist with or without corticosteroid.</p>
<p style="text-indent:-2em;margin-left:8em;">Day 1: Administer ~90 minutes prior to chemotherapy: IV: 3 mg/kg once; maximum dose: 115 mg/dose on day 1 only.</p>
<p style="text-indent:-2em;margin-left:8em;">Day 2 and 3: Administer ~90 minutes prior to chemotherapy: IV: 2 mg/kg once daily for 2 doses; maximum dose: 80 mg/dose; alternatively, may follow with oral aprepitant on days 2 and 3.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents ≤17 years:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Single-dose <i>NK<sub>1</sub> receptor antagonist </i> regimen: </i>
<b>Note: </b>Use only with single-day chemotherapy regimens. IV: 150 mg once, administered ~60 minutes prior to chemotherapy on day 1 only; use in combination with a 5-HT<sub>3</sub> antagonist with or without corticosteroid.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Three-day <i>NK<sub>1</sub> receptor antagonist </i> regimen:</i>
<b>Note: </b>May be used with single-day or multiday chemotherapy regimens<i>. </i>Use in combination with a 5-HT<sub>3</sub> antagonist with or without corticosteroid.</p>
<p style="text-indent:-2em;margin-left:8em;">Day 1: Administer ~60 minutes prior to chemotherapy: IV: 115 mg once.</p>
<p style="text-indent:-2em;margin-left:8em;">Day 2 and 3: Administer ~60 minutes prior to chemotherapy: IV: 80 mg once daily for 2 doses; alternatively, may follow with oral aprepitant on days 2 and 3.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥18 years: <i>Single-dose <i>NK<sub>1</sub> receptor antagonist </i> regimen<i>: </i></i>IV: 150 mg once, administer ~50 to 60 minutes prior to chemotherapy on day 1 only; in combination with a 5-HT<sub>3</sub> antagonist <b>and</b> corticosteroid.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9e1453b4-7648-4965-9c5e-ec94d9c4363f">Cyclic vomiting syndrome, supportive therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cyclic vomiting syndrome, supportive therapy:</b> Fosaprepitant has not been studied for cyclic vomiting syndrome. However, it may be considered as an IV option for supportive therapy, using doses similar to those shown to be efficacious for prevention of chemotherapy-induced nausea and vomiting, based on clinical experience and indirect evidence from using oral aprepitant for acute treatment of cyclic vomiting syndrome in pediatric patients ≥4 years of age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31241819','lexi-content-ref-24898244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31241819','lexi-content-ref-24898244'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51340827"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, adjustment is unlikely necessary as aprepitant is not renally excreted and does not require adjustment in renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: There are no dosage adjustments provided in the manufacturer's labeling; however, adjustment is unlikely necessary as aprepitant is not removed by hemodialysis.</p></div>
<div class="block dohp drugH1Div" id="F51340829"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Infants ≥6 months, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:2em;">Mild or moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (Child-Pugh class C): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); additional monitoring may be needed.</p></div>
<div class="block doa drugH1Div" id="F5657638"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9032" href="/d/html/9032.html" rel="external">see "Fosaprepitant: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dosing is for fosaprepitant (Emend IV); refer to the Aprepitant monograph for IV aprepitant (Cinvanti) dosing.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="170299cf-a590-4ce2-b509-66903788defc">Chemotherapy-induced nausea and vomiting, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chemotherapy-induced nausea and vomiting, prevention:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Highly emetogenic chemotherapy:</i>
<b>IV:</b> 150 mg on day 1 only (infusion should be completed ~30 minutes prior to chemotherapy). Administer in combination with a 5-HT<sub>3</sub> antagonist on day 1, dexamethasone on days 1 to 4, and olanzapine on days 1 to 4 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Moderately emetogenic chemotherapy:</i>
<b>IV:</b> 150 mg on day 1 only (infusion should be completed ~30 minutes prior to chemotherapy). Administer in combination with a 5-HT<sub>3</sub> antagonist and dexamethasone on day 1.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990494"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">There are no dosage adjustments provided in the manufacturer's labeling; however, due to modest decreases in protein binding of aprepitant, the AUC of pharmacologically active unbound drug is not significantly affected in patients with kidney disease.</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: Hemodialysis conducted 4 or 48 hours after dosing had no significant impact on aprepitant pharmacokinetics (a negligible amount of an aprepitant dose is recovered in the dialysate).</p></div>
<div class="block doha drugH1Div" id="F50987782"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild or moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (Child-Pugh class C): There is no dosage adjustment provided in the manufacturer's labeling (has not been studied); additional monitoring for adverse reactions may be needed.</p></div>
<div class="block adr drugH1Div" id="F5657528"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported with fosaprepitant (as part of a combination chemotherapy regimen) occurring at a higher frequency than standard antiemetic therapy. Also see aprepitant monograph for additional adverse reactions.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Fatigue (15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (13%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Peripheral neuropathy (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dyspepsia (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Neutropenia (8%), anemia (3%), leukopenia (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Infusion-site reaction (2% to 3%; includes induration at injection site, infusion-site pain, local pruritus, localized erythema)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Weakness (4%), limb pain (2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Anaphylactic shock, anaphylaxis, dyspnea, erythema, flushing, hypersensitivity reaction, hypotension, pruritus, skin rash, Stevens-Johnson syndrome, syncope, toxic epidermal necrolysis, urticaria</p></div>
<div class="block coi drugH1Div" id="F5657524"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to fosaprepitant or any component of the formulation; concurrent use with pimozide.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Concurrent use with astemizole, terfenadine, or cisapride</p></div>
<div class="block war drugH1Div" id="F5657525"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity reactions, including dyspnea, erythema, flushing, hypotension, syncope, and anaphylaxis/anaphylactic shock have been reported during infusions.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infusion-site reactions: Infusion-site reactions, including erythema, pain, edema, thrombophlebitis, pruritus, and injection-site induration have occurred; the majority of severe infusion-related reactions (including thrombophlebitis, vasculitis, and necrosis) have been reported with administration of concomitant vesicant (anthracycline-based) chemotherapy, particularly when associated with extravasation. Most reactions occurred with the first three exposures to single fosaprepitant injections; some reactions persisted ≥2 weeks.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p></div>
<div class="block prod-avail drugH1Div" id="F58595871"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Focinvez: FDA approved August 2023; anticipated availability currently unknown. Information pertaining to this product within the monograph is pending revision. Focinvez is a 150 mg/50 mL ready to use single-dose vial and is indicated in adults and pediatric patients 6 months of age and older, in combination with other antiemetic agents, for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin or delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. Consult prescribing information for additional information.</p></div>
<div class="block foc drugH1Div" id="F5657664"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 150 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Emend: 150 mg (1 ea) [contains edetate (edta) disodium, lactose, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 150 mg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F5657515"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F6255767"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Emend Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $401.56</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Fosaprepitant Dimeglumine Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $30.00 - $401.56</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868942"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Emend: 150 mg (1 ea) [contains disodium edta, lactose, polysorbate 80]</p></div>
<div class="block admp drugH1Div" id="F52614264"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral:</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Administer by IV infusion.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months and Children &lt;12 years: Infuse over 60 minutes; administer ~90 minutes prior to chemotherapy to ensure completion 30 minutes prior to the start of chemotherapy.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents &lt;17 years: Infuse over 30 minutes; administer ~60 minutes prior to chemotherapy to ensure completion 30 minutes prior to the start of chemotherapy.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥18 years: Infuse over 20 to 30 minutes; administer ~50 to 60 minutes prior to chemotherapy to ensure completion 30 minutes prior to the start of chemotherapy.</p></div>
<div class="block adm drugH1Div" id="F5657642"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Infuse over 20 to 30 minutes; infusion should be completed ~30 minutes prior to chemotherapy.</p>
<p style="text-indent:-2em;margin-left:2em;">Avoid infusing fosaprepitant into small veins or through a butterfly catheter. If a severe infusion-site reaction occurs, stop infusion and manage appropriately.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Administration information is for fosaprepitant (Emend IV); refer to the aprepitant monograph for IV aprepitant (Cinvanti) administration.</p></div>
<div class="block sts drugH1Div" id="F5657551"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store intact vials at 2°C to 8°C (36°F to 46°F). Solutions diluted  to 1 mg/mL for infusion are stable for 24 hours at room temperature at ≤25°C (≤77°F). Solutions diluted in NS to a final volume of 250 mL (0.6 mg/mL) should be administered within 24 hours (data on file [Merck 2013]).</p></div>
<div class="block usep drugH1Div" id="F53570242"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including cisplatin in combination with other antiemetic agents; prevention of delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) in combination with other antiemetic agents (All indications: FDA approved in ages ≥6 months and adults).</p></div>
<div class="block mst drugH1Div" id="F5657514"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Fosaprepitant may be confused with aprepitant, fosamprenavir, fosnetupitant/palonosetron, fospropofol, fostamatinib, rolapitant</p>
<p style="text-indent:-2em;margin-left:4em;">Fosaprepitant (Emend IV) may be confused with aprepitant IV (Cinvanti)</p>
<p style="text-indent:-2em;margin-left:4em;">Emend for Injection (fosaprepitant) may be confused with Emend oral (aprepitant) which is an oral capsule formulation</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F5657546"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor), CYP2C19 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP3A4 (weak); <b>Induces</b> CYP2C9 (weak)</p></div>
<div class="block dri drugH1Div" id="F5657545"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">ALPRAZolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ALPRAZolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): CYP3A4 Inhibitors (Weak) may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Fosaprepitant. Specifically, CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite aprepitant.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Fosaprepitant. Specifically, CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite aprepitant.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Fosaprepitant.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Fosaprepitant.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexAMETHasone (Systemic): Fosaprepitant may increase the serum concentration of DexAMETHasone (Systemic).  Management: Reduce the dexamethasone dose 50% when coadministered with aprepitant. Aprepitant prescribing information incorporates this recommendation into the dose provided for dexamethasone; further reduction is not necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dofetilide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Finerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flibanserin: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Flibanserin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hormonal Contraceptives: Fosaprepitant may decrease the serum concentration of Hormonal Contraceptives.  Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration with fosaprepitant, and to continue back-up contraception for 28 days after discontinuing fosaprepitant to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ifosfamide: Fosaprepitant may enhance the adverse/toxic effect of Ifosfamide. Specifically, the risk for ifosfamide induced encephalopathy may be increased. Fosaprepitant may increase serum concentrations of the active metabolite(s) of Ifosfamide. Specifically, concentrations of the active and toxic metabolites of ifosfamide may increase. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Ixabepilone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lemborexant.  Management: The maximum recommended dosage of lemborexant is 5 mg, no more than once per night, when coadministered with weak CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Patients on lomitapide 5 mg/day may continue that dose. Patients taking lomitapide 10 mg/day or more should decrease the lomitapide dose by half. The lomitapide dose may then be titrated up to a max adult dose of 30 mg/day.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">MethylPREDNISolone: Fosaprepitant may increase the serum concentration of MethylPREDNISolone.  Management: Decrease the oral methylprednisolone dose by 50%, and decrease the intravenous methylprednisolone dose by 25%, when combined with fosaprepitant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midazolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Midazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiMODipine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: Fosaprepitant may increase the serum concentration of Pimozide. The active metabolite aprepitant is likely responsible for this effect. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simvastatin: CYP3A4 Inhibitors (Weak) may increase serum concentrations of the active metabolite(s) of Simvastatin. CYP3A4 Inhibitors (Weak) may increase the serum concentration of Simvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Sirolimus (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Sirolimus (Protein Bound).  Management: Reduce the dose of protein bound sirolimus to 56 mg/m<sup>2</sup> when used concomitantly with a weak CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triazolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Triazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Ubrogepant.  Management: In patients taking weak CYP3A4 inhibitors, the initial and second dose (given at least 2 hours later if needed) of ubrogepant should be limited to 50 mg.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Fosaprepitant may decrease the serum concentration of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F5657549"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Aprepitant serum concentration may be increased when taken with grapefruit juice. Management: Avoid concurrent use. </p></div>
<div class="block rep_considerations drugH1Div" id="F49306734"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Efficacy of hormonal contraceptive may be reduced; alternative or additional methods of contraception should be used during treatment with fosaprepitant and for at least 1 month following the last fosaprepitant dose.</p></div>
<div class="block pri drugH1Div" id="F5657521"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Adverse events were not observed in animal reproduction studies.</p></div>
<div class="block mopp drugH1Div" id="F53570243"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Immediate hypersensitivity reactions during infusion (anaphylaxis, dyspnea, erythema, or flushing).  If reaction occurs, infusion should be stopped and not reinitiated.  </p></div>
<div class="block pha drugH1Div" id="F5657626"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Fosaprepitant is a prodrug of aprepitant, a substance P/neurokinin 1 (NK1) receptor antagonist. Fosaprepitant is rapidly converted to aprepitant, which prevents acute and delayed vomiting by inhibiting the substance P/neurokinin 1 (NK1) receptor; also augments the antiemetic activity of the 5-HT<sub>3</sub> receptor antagonist and corticosteroid activity and inhibits chemotherapy-induced emesis.</p></div>
<div class="block phk drugH1Div" id="F5657628"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Aprepitant: V<sub>d</sub>: ~70 L; crosses the blood-brain barrier</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Aprepitant: &gt;95%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: </p>
<p style="text-indent:-2em;margin-left:4em;">Fosaprepitant: Hepatic and extrahepatic; rapidly (within 30 minutes after the end of infusion) converted to aprepitant (nearly complete conversion) </p>
<p style="text-indent:-2em;margin-left:4em;">Aprepitant: Hepatic via CYP3A4 (major); CYP1A2 and CYP2C19 (minor); forms 7 weakly-active metabolites</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Aprepitant: ~9 to 13 hours </p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: Fosaprepitant is converted to aprepitant within 30 minutes after the end of infusion</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (57%); feces (45%)</p></div>
<div class="block phksp drugH1Div" id="F51192659"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Altered kidney function: Following a single oral aprepitant 240 mg dose in patients with CrCl &lt;30 mL/minute/1.73 m<sup>2</sup>, the AUC of total aprepitant (unbound and protein bound) decreased by 21% and C<sub>max</sub> decreased by 32% compared with healthy subjects. In patients with ESRD undergoing hemodialysis, the AUC of total aprepitant decreased by 42% and C<sub>max</sub> decreased by 32%.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F11390215"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Emend</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Ivemend</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Fosaprepitant | Ivemend</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Emend</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Ivemend</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Emend | Fosaprepitanto dimeglumina</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Ivemend</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Fosaprepitant dimeglumine | Shan qi | Tan neng</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Apritant | Emend | Fosemred</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Fosaprepitant hikma | Fosaprepitant stada | Fosaprepitant Tillomed</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Emend</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Ivemend</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Ivemend</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Fosaprepitant accord | Fosaprepitant hikma | Fosaprepitant Tillomed | Ivemend</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Fosaprepitant</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Ivemend</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Ivemend</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Ivemend</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Ivemend</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Emend</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Ivemend</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Amitant | Emend | Fosa | Fosalon | Fosapine | Fosaport | Fosapp | Fosapretero | Fospritant</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Fosaprepitant accord | Fosaprepitant hikma | Ivemend</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Ivemend</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Fosaprepitant nk | Proemend</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Apritant</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Emend</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Ivemend</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Ivemend</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Ivemend</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Emend</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Ivemend</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Ivemend</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Apritant | Ivemend</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Ivemend</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Emend | Fosaprepitant</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Fosaprepitant accord | Fosaprepitant hikma | Ivemend</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Apritant IV | Ivemend</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Ivemend</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Emend</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Emend | Fosaprepitant spc</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Fosaprepitant accord | Ivemend</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Emend</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Ivemend</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Ivemend</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Ivemend</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Fosemazon</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Emend</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Emend</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Emetend | Fosemred | Ivemend</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosaprepitant-pediatric-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control and Prevention (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosaprepitant-pediatric-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29651918">
<a name="29651918"></a>Chau E, Lundberg J, Phillips G, Berger M, Wesolowski R. Updated report on incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant. <i>J Oncol Pharm Pract</i>. 2019;25(5):1053-1057. doi: 10.1177/1078155218769347.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosaprepitant-pediatric-drug-information/abstract-text/29651918/pubmed" id="29651918" target="_blank">29651918</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24898244">
<a name="24898244"></a>Cristofori F, Thapar N, Saliakellis E, et al. Efficacy of the neurokinin-1 receptor antagonist aprepitant in children with cyclical vomiting syndrome. <i>Aliment Pharmacol Ther</i>. 2014;40(3):309-317. doi:10.1111/apt.12822<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosaprepitant-pediatric-drug-information/abstract-text/24898244/pubmed" id="24898244" target="_blank">24898244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Merck.1">
<a name="Merck.1"></a>Emend (fosaprepitant) for injection [prescribing information]. Whitehouse Station, NJ: Merck Sharp &amp; Dohme Corp; April 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Merck.2">
<a name="Merck.2"></a>Emend (fosaprepitant) for injection [prescribing information]. Whitehouse Station, NJ: Merck Sharp &amp; Dohme Corp; May 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Merck.3">
<a name="Merck.3"></a>Emend IV (fosaprepitant) [product monograph]. Kirkland, Quebec, Canada: Merck Canada Inc; October 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21383291">
<a name="21383291"></a>Grunberg S, Chua D, Maru A, et al, “Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol -- EASE,” <i>J Clin Oncol</i>, 2011, 29(11):1495-501.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosaprepitant-pediatric-drug-information/abstract-text/21383291/pubmed" id="21383291" target="_blank">21383291</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32658626">
<a name="32658626"></a>Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update. <i>J Clin Oncol</i>. 2020;38(24):2782-2797. doi:10.1200/JCO.20.01296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosaprepitant-pediatric-drug-information/abstract-text/32658626/pubmed" id="32658626" target="_blank">32658626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosaprepitant-pediatric-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosaprepitant-pediatric-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27664248">
<a name="27664248"></a>Roila F, Molassiotis A, Herrstedt J, et al; participants of the MASCC/ESMO Consensus Conference Copenhagen 2015. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. <i>Ann Oncol</i>. 2016;27(suppl 5):v119-v133.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosaprepitant-pediatric-drug-information/abstract-text/27664248/pubmed" id="27664248" target="_blank">27664248</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosaprepitant-pediatric-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12115394">
<a name="12115394"></a>Van Belle S, Lichinitser SR, Navari RM, et al,” Prevention of Cisplatin-Induced Acute and Delayed Emesis by the Selective Neurokinin-1 Antagonists, L-758,298 and MK-869,” <i>Cancer</i>, 2002, 94(11):3032-41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosaprepitant-pediatric-drug-information/abstract-text/12115394/pubmed" id="12115394" target="_blank">12115394</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31241819">
<a name="31241819"></a>Venkatesan T, Levinthal DJ, Tarbell SE, et al. Guidelines on management of cyclic vomiting syndrome in adults by the American Neurogastroenterology and Motility Society and the Cyclic Vomiting Syndrome Association. <i>Neurogastroenterol Motil</i>. 2019;31(suppl 2):e13604. doi:10.1111/nmo.13604<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosaprepitant-pediatric-drug-information/abstract-text/31241819/pubmed" id="31241819" target="_blank">31241819</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26449391">
<a name="26449391"></a>Weinstein C, Jordan K, Green SA, et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial. <i>Ann Oncol.</i> 2016;27(1):172-178.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosaprepitant-pediatric-drug-information/abstract-text/26449391/pubmed" id="26449391" target="_blank">26449391</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 17060 Version 421.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
